AbbVie to File for Dual Hep C Treatments Offering Shorter Treatment Time than Harvoni, Sovaldi

AbbVie plans to submit a marketing authorization application early next year in Japan for its new interferon (IFN)-free hepatitis C treatments, the NS3/4A protease inhibitor glecaprevir and the NS5A inhibitor pibrentasvir, which the company is developing as a dual oral...read more